



Combined Locoregional-Immunotherapy for Cancer Treatment

Guest Editors:

Dr. Heegon Kim

Department of Radiology,
Northwestern University Feinberg
School of Medicine, Chicago, IL
60611, USA

Prof. Dr. Dong-Hyun Kim

Department of Radiology,
Northwestern University
Feinberg, School of Medicine,
Chicago, IL 60611, USA

Deadline for manuscript
submissions:

closed (20 August 2021)

Message from the Guest Editors

Immunotherapy has changed the landscape of cancer treatment in the past several years. The systemic administration of immune checkpoint inhibitors (ICIs), targeting PD-1, PD-L1, or CTLA-4, is the pillar of current immunotherapy. However, it is notable that ICIs have limited efficacy as monotherapy, and their greatest potential lies in combination with other treatments that can trigger or augment anti-tumour immune responses.

Accumulating preclinical data suggest that the locoregional delivery of immunotherapy agents (e.g., TLR/STING agonists, antibodies, or viruses) can induce robust systemic antitumor immunity in various types of cancers. However, one of the major setbacks of locoregional immunotherapy is that many cancers in the clinic are not easily accessible compared with preclinical tumour models. Therefore, its clinical utilization will inevitably require image-guidance. The purpose of this Special Issue is to collect studies regarding locoregional immunotherapies from researchers in the field of immunoncology and interventional oncology in order to promote new opportunities and perspectives by bridging the gap between the fields.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics,
Ernest Mario School of
Pharmacy, Rutgers University,
Piscataway, NJ 08854, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Contact Us

Pharmaceutics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceutics
pharmaceutics@mdpi.com
X@MDPIpharma